Lipoic acid (LA), an oral antioxidant supplement, was not associated with greater improvements in timed walking speed or other clinical outcomes in patients with progressive multiple sclerosis (MS) ...
Morgan Stanley chief equity strategist Michael Wilson says the consensus is significantly underestimating the combined impact of multiple bullish catalysts heading into 2026, with the year’s big ...
Ongoing clinical trials are exploring therapies like tolebrutinib, fingolimod, and ocrelizumab, focusing on efficacy and safety in diverse patient populations. The MUSETTE trial confirmed that the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback